Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

ARS Pharma enters agreement with ALK-Abelló to co-promote neffy, a needle-free treatment for type I allergic reactions: San Diego Monday, May 5, 2025, 12:00 Hrs [IST] ARS Pharmac ...

Discover AQST's growth potential with Anaphylm's FDA approval by Q2'25 targeting $1B revenue. Learn DCF valuations offering ...